Literature DB >> 28634198

The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.

Parag Mahale1,2,3, Eric A Engels1, Ruosha Li4, Harrys A Torres5, Lu-Yu Hwang2, Eric L Brown2, Jennifer R Kramer2,3,6.   

Abstract

BACKGROUND AND AIM: Chronic HCV infection is associated with several extrahepatic manifestations (EHMs). Data on the effect of sustained virological response (SVR) on the risk of EHMs are limited.
METHODS: We conducted a retrospective cohort study using data of patients from the US Veterans Affairs HCV Clinical Case Registry who had a positive HCV RNA test (10/1999-08/2009). Patients receiving interferon-based antiviral therapy (AVT) were identified. SVR was defined as negative HCV RNA at least 12 weeks after end of AVT. Risks of eight incident EHMs were evaluated in Cox regression models.
RESULTS: Of the 160 875 HCV-infected veterans, 31 143 (19.4%) received AVT, of whom 10 575 (33.9%) experienced SVR. EHM risk was reduced in the SVR group compared with untreated patients for mixed cryoglobulinaemia (adjusted HR (aHR)=0.61; 95% CI 0.39 to 0.94), glomerulonephritis (aHR=0.62; 95% CI 0.48 to 0.79), porphyria cutanea tarda (PCT) (aHR=0.41; 95% CI 0.20 to 0.83), non-Hodgkin's lymphoma (NHL) (aHR=0.64; 95% CI 0.43 to 0.95), diabetes (aHR=0.82; 95% CI 0.76 to 0.88) and stroke (aHR=0.84; 95% CI 0.74 to 0.94), but not for lichen planus (aHR=1.11; 95% CI 0.78 to 1.56) or coronary heart disease (aHR=1.12; 95% CI 0.81 to 1.56). Risk reductions were also observed when patients with SVR were compared with treated patients without SVR for mixed cryoglobulinaemia, glomerulonephritis, PCT and diabetes. Significant reductions in the magnitude of aHRs towards the null with increasing time to initiation of AVT after HCV diagnosis were observed for glomerulonephritis, NHL and stroke.
CONCLUSIONS: Risks of several EHMs of HCV infection are reduced after AVT with SVR. However, early initiation of AVT may be required to reduce the risk of glomerulonephritis, NHL and stroke. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Hepatitis C virus; antiviral therapy; extrahepatic manifestations; sustained virological response

Mesh:

Substances:

Year:  2017        PMID: 28634198      PMCID: PMC6292199          DOI: 10.1136/gutjnl-2017-313983

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  52 in total

1.  Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.

Authors:  Karin Kozbial; Stephan Moser; Remy Schwarzer; Hermann Laferl; Ramona Al-Zoairy; Rudolf Stauber; Albert F Stättermayer; Sandra Beinhardt; Ivo Graziadei; Clarissa Freissmuth; Andreas Maieron; Michael Gschwantler; Michael Strasser; Markus Peck-Radosalvjevic; Michael Trauner; Harald Hofer; Peter Ferenci
Journal:  J Hepatol       Date:  2016-06-16       Impact factor: 25.083

Review 2.  Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.

Authors:  Zobair Younossi; Haesuk Park; Linda Henry; Ayoade Adeyemi; Maria Stepanova
Journal:  Gastroenterology       Date:  2016-02-26       Impact factor: 22.682

3.  Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

Authors:  Donna L White; Vlad Ratziu; Hashem B El-Serag
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

4.  Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.

Authors:  Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters
Journal:  Clin Gastroenterol Hepatol       Date:  2008-04       Impact factor: 11.382

5.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.

Authors:  Jianmeng Chen; Jeffry Florian; Wendy Carter; Russell D Fleischer; Thomas S Hammerstrom; Pravin R Jadhav; Wen Zeng; Jeffrey Murray; Debra Birnkrant
Journal:  Gastroenterology       Date:  2013-03-05       Impact factor: 22.682

6.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

7.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.

Authors:  R Misiani; P Bellavita; D Fenili; G Borelli; D Marchesi; M Massazza; G Vendramin; B Comotti; E Tanzi; G Scudeller
Journal:  Ann Intern Med       Date:  1992-10-01       Impact factor: 25.391

8.  Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C.

Authors:  U Protzer; F R Ochsendorf; A Leopolder-Ochsendorf; K H Holtermüller
Journal:  Gastroenterology       Date:  1993-03       Impact factor: 22.682

9.  Hepatitis C virus infection and the risk of coronary disease.

Authors:  Adeel A Butt; Wang Xiaoqiang; Matthew Budoff; David Leaf; Lewis H Kuller; Amy C Justice
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

View more
  30 in total

1.  The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.

Authors:  Hashem B El-Serag; Israel C Christie; Amy Puenpatom; Diana Castillo; Fasiha Kanwal; Jennifer R Kramer
Journal:  Aliment Pharmacol Ther       Date:  2019-04-01       Impact factor: 8.171

2.  Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer.

Authors:  Minas P Economides; Moran Amit; Parag S Mahale; Jeff J Hosry; Ying Jiang; Uddalak Bharadwaj; Erich M Sturgis; Harrys A Torres
Journal:  Cancer       Date:  2017-11-17       Impact factor: 6.860

3.  Extrahepatic Benefits Achieved With Sustained Virologic Response in Patients With Hepatitis C Virus Infection.

Authors:  Marcelo Kugelmas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-09

4.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.

Authors:  Jia Li; Stuart C Gordon; Loralee B Rupp; Talan Zhang; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Mei Lu
Journal:  Aliment Pharmacol Ther       Date:  2019-01-16       Impact factor: 8.171

6.  Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.

Authors:  Jinmin Jung; Jae Hyun Kwon; Gi-Won Song; Eun-Young Tak; Vavara A Kirchner; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2018-04-20       Impact factor: 3.452

7.  Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.

Authors:  Wei Wang; Vincent Lo Re; Yi Guo; Hong Xiao; Joshua Brown; Haesuk Park
Journal:  Aliment Pharmacol Ther       Date:  2020-09-15       Impact factor: 8.171

Review 8.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07

9.  Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.

Authors:  Charitha Gowda; Vincent Lo Re
Journal:  Curr Hepatol Rep       Date:  2018-03-24

Review 10.  Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.